Amylyx Pharmaceuticals Advances Avexitide Toward Phase 3 Data
CAMBRIDGE, Mass., August 6, 2026 Amylyx Pharmaceuticals reported its second quarter 2026 financial results, highlighting significant progress across its...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., August 6, 2026 Amylyx Pharmaceuticals reported its second quarter 2026 financial results, highlighting significant progress across its...
TOKYO, August 7, 2026 Astellas Pharma announced the submission of a New Drug Application (NDA) to Japan’s Ministry of...
WAYNE, Pa., August 6, 2026 Aclaris Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
NANJING, China, August 4, 2026 Leads Biolabs announced that its partner Oblenio Bio, a company jointly established with Aditum...
HONG KONG, August 5, 2026 Insilico Medicine has announced the nomination of ISM9077 as its 32nd Preclinical Candidate (PCC)...
SUNNYVALE, Calif., Aug. 3, 2026 Ceribell, Inc. has secured a significant reimbursement milestone after the U.S. Centers for Medicare...
ROCKVILLE, Md. & RICHMOND, Va., Aug. 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals announced they have entered into a...
PARIS, France, July 30, 2026 Abivax SA announced the successful completion of a positive pre-New Drug Application (pre-NDA) interaction...
LA JOLLA, Calif., July 29, 2026 CalciMedica, Inc. has announced a significant regulatory milestone after reaching alignment with the...
MONTEREY, Calif., July 29, 2026 Johnson & Johnson has completed its $1 billion acquisition of Firefly Bio, Inc., significantly...
